These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
268 related articles for article (PubMed ID: 18650621)
21. Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma. Landry J; Catalano PJ; Staley C; Harris W; Hoffman J; Talamonti M; Xu N; Cooper H; Benson AB J Surg Oncol; 2010 Jun; 101(7):587-92. PubMed ID: 20461765 [TBL] [Abstract][Full Text] [Related]
22. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. Louvet C; Labianca R; Hammel P; Lledo G; Zampino MG; André T; Zaniboni A; Ducreux M; Aitini E; Taïeb J; Faroux R; Lepere C; de Gramont A; ; J Clin Oncol; 2005 May; 23(15):3509-16. PubMed ID: 15908661 [TBL] [Abstract][Full Text] [Related]
23. Biweekly low-dose sequential gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (GFP): a highly active novel therapy for metastatic adenocarcinoma of the exocrine pancreas. Araneo M; Bruckner HW; Grossbard ML; Frager D; Homel P; Marino J; DeGregorio P; Mortazabi F; Firoozi K; Jindal K; Kozuch P Cancer Invest; 2003; 21(4):489-96. PubMed ID: 14533437 [TBL] [Abstract][Full Text] [Related]
24. Patterns of Failure for Lymph Node-Positive Resected Pancreatic Adenocarcinoma After Adjuvant Radiotherapy or Gemcitabine-based Chemotherapy Alone. McDonald AM; Dulaney CR; López-Araujo J; Posey JA; Keene KS; Christein JD; Heslin MJ; Wood TE; Jacob R J Gastrointest Cancer; 2015 Jun; 46(2):149-55. PubMed ID: 25782589 [TBL] [Abstract][Full Text] [Related]
25. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. Regine WF; Winter KA; Abrams RA; Safran H; Hoffman JP; Konski A; Benson AB; Macdonald JS; Kudrimoti MR; Fromm ML; Haddock MG; Schaefer P; Willett CG; Rich TA JAMA; 2008 Mar; 299(9):1019-26. PubMed ID: 18319412 [TBL] [Abstract][Full Text] [Related]
26. Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer. Hidalgo M; Castellano D; Paz-Ares L; Gravalos C; Diaz-Puente M; Hitt R; Alonso S; Cortes-Funes H J Clin Oncol; 1999 Feb; 17(2):585-92. PubMed ID: 10080603 [TBL] [Abstract][Full Text] [Related]
27. Phase 1 pharmacogenetic and pharmacodynamic study of sorafenib with concurrent radiation therapy and gemcitabine in locally advanced unresectable pancreatic cancer. Chiorean EG; Schneider BP; Akisik FM; Perkins SM; Anderson S; Johnson CS; DeWitt J; Helft P; Clark R; Johnston EL; Spittler AJ; Deluca J; Bu G; Shahda S; Loehrer PJ; Sandrasegaran K; Cardenes HR Int J Radiat Oncol Biol Phys; 2014 Jun; 89(2):284-91. PubMed ID: 24726286 [TBL] [Abstract][Full Text] [Related]
28. Results and patterns of failure in patients treated with adjuvant combined chemoradiation therapy for resected pancreatic adenocarcinoma. Hattangadi JA; Hong TS; Yeap BY; Mamon HJ Cancer; 2009 Aug; 115(16):3640-50. PubMed ID: 19514088 [TBL] [Abstract][Full Text] [Related]
29. A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma. Duffy A; Kortmansky J; Schwartz GK; Capanu M; Puleio S; Minsky B; Saltz L; Kelsen DP; O'Reilly EM Ann Oncol; 2008 Jan; 19(1):86-91. PubMed ID: 17878176 [TBL] [Abstract][Full Text] [Related]
30. Neoadjuvant docetaxel-based chemoradiation for resectable adenocarcinoma of the pancreas: New neoadjuvant regimen was safe and provided an interesting pathologic response. Turrini O; Ychou M; Moureau-Zabotto L; Rouanet P; Giovannini M; Moutardier V; Azria D; Delpero JR; Viret F Eur J Surg Oncol; 2010 Oct; 36(10):987-92. PubMed ID: 20828979 [TBL] [Abstract][Full Text] [Related]
31. Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer. Lee S; Oh SY; Kim BG; Kwon HC; Kim SH; Rho MH; Kim YH; Rho MS; Jeong JS; Kim HJ Am J Clin Oncol; 2009 Aug; 32(4):348-52. PubMed ID: 19363436 [TBL] [Abstract][Full Text] [Related]
32. Survival after chemoradiation in resected pancreatic cancer: the impact of adjuvant gemcitabine. Baschnagel A; Shah C; Margolis J; Nadeau L; Stein J; Jury R; Robertson JM Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):e331-5. PubMed ID: 22420967 [TBL] [Abstract][Full Text] [Related]
33. Safety and efficacy of adjuvant chemoradiation therapy with capecitabine after resection of pancreatic ductal adenocarcinoma: a retrospective review. Kim ST; Lee J; Park SH; Lee JK; Lee KT; Lee KH; Heo JS; Choi SH; Choi DW; Park YS; Lim HY; Kang WK; Jang KT; Park HC; Lim DH; Park JO Am J Clin Oncol; 2012 Oct; 35(5):432-8. PubMed ID: 21606820 [TBL] [Abstract][Full Text] [Related]
34. Preoperative chemoradiation for adenocarcinoma of the pancreas and duodenum. Coia L; Hoffman J; Scher R; Weese J; Solin L; Weiner L; Eisenberg B; Paul A; Hanks G Int J Radiat Oncol Biol Phys; 1994 Aug; 30(1):161-7. PubMed ID: 8083109 [TBL] [Abstract][Full Text] [Related]
35. A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer. Ko AH; Quivey JM; Venook AP; Bergsland EK; Dito E; Schillinger B; Tempero MA Int J Radiat Oncol Biol Phys; 2007 Jul; 68(3):809-16. PubMed ID: 17363191 [TBL] [Abstract][Full Text] [Related]
36. Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group. Ettrich TJ; Berger AW; Perkhofer L; Daum S; König A; Dickhut A; Wittel U; Wille K; Geissler M; Algül H; Gallmeier E; Atzpodien J; Kornmann M; Muche R; Prasnikar N; Tannapfel A; Reinacher-Schick A; Uhl W; Seufferlein T BMC Cancer; 2018 Dec; 18(1):1298. PubMed ID: 30594153 [TBL] [Abstract][Full Text] [Related]
37. Phase II study of a fixed dose-rate infusion of gemcitabine associated with uracil/tegafur in advanced carcinoma of the pancreas. Feliu J; Mel R; Borrega P; López Gómez L; Escudero P; Dorta J; Castro J; Vázquez-Estévez SE; Bolaños M; Espinosa E; González Barón M; Ann Oncol; 2002 Nov; 13(11):1756-62. PubMed ID: 12419748 [TBL] [Abstract][Full Text] [Related]
38. Identifying Clinical Factors Which Predict for Early Failure Patterns Following Resection for Pancreatic Adenocarcinoma in Patients Who Received Adjuvant Chemotherapy Without Chemoradiation. Walston S; Salloum J; Grieco C; Wuthrick E; Diaz DA; Barney C; Manilchuk A; Schmidt C; Dillhoff M; Pawlik TM; Williams TM Am J Clin Oncol; 2018 Dec; 41(12):1185-1192. PubMed ID: 29727311 [TBL] [Abstract][Full Text] [Related]
39. Phase II trial of gemcitabine, epirubicin and granulocyte colony-stimulating factor in patients with advanced pancreatic adenocarcinoma. Scheithauer W; Kornek GV; Raderer M; Hejna M; Valencak J; Miholic J; Kovats E; Lang F; Funovics J; Bareck E; Depisch D Br J Cancer; 1999 Aug; 80(11):1797-802. PubMed ID: 10468299 [TBL] [Abstract][Full Text] [Related]
40. Neoadjuvant chemoradiation and duration of chemotherapy before surgical resection for pancreatic cancer: does time interval between radiotherapy and surgery matter? Chen KT; Devarajan K; Milestone BN; Cooper HS; Denlinger C; Cohen SJ; Meyer JE; Hoffman JP Ann Surg Oncol; 2014 Feb; 21(2):662-9. PubMed ID: 24276638 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]